Enveric Biosciences Inc

Enveric Biosciences, Inc. is a biotechnology company focused on developing small molecule neuroplastogenic therapeutics for psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops the EVM401 series, which includes novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds targeting addiction and neuropsychiatric disorders. Additionally, it has Psybrary, a proprietary library. Enveric Biosciences is headquartered in Cambridge, Massachusetts.